Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000100

General Counsel sold 10,000 shares at an average $93.64 ($936,417)

  • General Counsel acquired 10,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Quinlan Paul T General Counsel 2026-09-21 Option exercise 10b5-1 +10,000 $7.80 $78,000 39,995 D: show line 1 in the form
Quinlan Paul T General Counsel 2026-09-21 Sale 10b5-1 −2,900 $92.37 $267,870 37,095 D: show line 2 in the form
Quinlan Paul T General Counsel 2026-09-21 Sale 10b5-1 −3,832 $93.32 $357,592 33,263 D: show line 3 in the form
Quinlan Paul T General Counsel 2026-09-21 Sale 10b5-1 −601 $94.44 $56,760 32,662 D: show line 4 in the form
Quinlan Paul T General Counsel 2026-09-21 Sale 10b5-1 −2,667 $95.31 $254,196 29,995 D: show line 5 in the form
Open-market sales · 10,000 sh · avg $93.64 · $936,417

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Quinlan Paul T General Counsel 2026-09-21 Option exercise · Employee Warrant (right to buy) 10b5-1 −10,000 79,996 D: show line 6 in the form
Loading xslF345X06/form4.xml…